Stüve O - Search Results

1

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Stangel M, Fredrikson S, Meinl E, Petzold A, Stüve O, Tumani H. Stangel M, et al. Among authors: stuve o. Nat Rev Neurol. 2013 May;9(5):267-76. doi: 10.1038/nrneurol.2013.41. Epub 2013 Mar 26. Nat Rev Neurol. 2013. PMID: 23528543 Review.

2

Are statins a treatment option for multiple sclerosis?

Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Neuhaus O, et al. Among authors: stuve o. Lancet Neurol. 2004 Jun;3(6):369-71. doi: 10.1016/S1474-4422(04)00770-7. Lancet Neurol. 2004. PMID: 15157852 Review.

3

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Stüve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, Kieseier BC. Stüve O, et al. Arch Neurol. 2005 Oct;62(10):1620-3. doi: 10.1001/archneur.62.10.1620. Arch Neurol. 2005. PMID: 16216948

4

Immune surveillance in multiple sclerosis patients treated with natalizumab.

Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK. Stüve O, et al. Ann Neurol. 2006 May;59(5):743-7. doi: 10.1002/ana.20858. Ann Neurol. 2006. PMID: 16634029

5

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK. Stüve O, et al. Arch Neurol. 2006 Oct;63(10):1383-7. doi: 10.1001/archneur.63.10.1383. Arch Neurol. 2006. PMID: 17030653 Clinical Trial.

6

Multiple sclerosis therapy: an update on recently finished trials.

Kleinschnitz C, Meuth SG, Stüve O, Kieseier B, Wiendl H. Kleinschnitz C, et al. Among authors: stuve o. J Neurol. 2007 Nov;254(11):1473-90. doi: 10.1007/s00415-007-0684-7. Epub 2007 Nov 15. J Neurol. 2007. PMID: 18004638 Review.

7

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.

Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O; Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine. Boster A, et al. Among authors: stuve o. Lancet Neurol. 2008 Feb;7(2):173-83. doi: 10.1016/S1474-4422(08)70020-6. Lancet Neurol. 2008. PMID: 18207115 Review.

8

Immunomodulatory treatment strategies in multiple sclerosis.

Kieseier BC, Wiendl H, Leussink VI, Stüve O. Kieseier BC, et al. Among authors: stuve o. J Neurol. 2008 Dec;255 Suppl 6:15-21. doi: 10.1007/s00415-008-6004-z. J Neurol. 2008. PMID: 19300955 Review.

9

Monoclonal antibodies in the therapy of multiple sclerosis: an overview.

Rommer PS, Stüve O, Goertsches R, Mix E, Zettl UK. Rommer PS, et al. Among authors: stuve o. J Neurol. 2008 Dec;255 Suppl 6:28-35. doi: 10.1007/s00415-008-6006-x. J Neurol. 2008. PMID: 19300957 Review.

10

Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.

Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Awad A, et al. Among authors: stuve o. J Neuroimmunol. 2010 Feb 26;219(1-2):1-7. doi: 10.1016/j.jneuroim.2009.09.002. Epub 2009 Sep 25. J Neuroimmunol. 2010. PMID: 19782408 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

310 results

Search Page